Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of...(ntract research organization serving the...)

Date:9/10/2008

ntract research organization serving the biopharmaceutical and medical device industries, and Chief Executive Officer and President of Omnicomm Systems, a Nasdaq company that is dedicated to helping the world's pharmaceutical, biotechnology, CROs, research and medical device organizations to maximize the value of their clinical research investments through the use of innovative and progressive technologies. Dr. Ginsberg has significant experience in the medical safety and pharmacovigilance fields and has been a principal investigator in several hundred clinical trials in a wide variety of indications. Dr. Ginsberg has authored numerous publications, including "The Investigator's Guide to Clinical Research" and "How to Become a Successful Clinical Investigator."

"I am very excited to be a part of Encorium," commented Dr. Ginsberg. "I believe the Company is well positioned to become a leader in the clinical research industry. My role will be to exploit the Company's enormous potential and I very much look forward to the challenges ahead."

Board of Director Changes

The Company also announced two changes to its Board of Directors, appointing David Morra effective immediately and appointing a current director of Prologue Research International, Inc. with extensive executive level healthcare management experience to be effective upon the closing of the acquisition of Prologue. The newly appointed directors will replace Scott M. Jenkins and Christopher F. Meshginpoosh, who have tendered their resignation from the Company's Board of Directors, effective immediately. With these changes, Encorium's Board of Directors will remain at five members and will consist of a majority of independent directors.

Mr. Morra, 53, is a Managing Director of Union Partners, LLC, a private equity and performance acceleration firm. In this capacity, he provides executive oversight for consulting engagements and acquisition activities for targeted companies. Previously
'/>"/>

SOURCE Encorium Group, Inc. Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development